» Articles » PMID: 29627826

Meibomian Gland Dysfunction in Primary and Secondary Sjögren Syndrome

Overview
Journal Ophthalmic Res
Specialty Ophthalmology
Date 2018 Apr 9
PMID 29627826
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: We hypothesized that women with primary (pSS) and secondary Sjögren syndrome (sSS; with systemic lupus erythematosus [SLE] or rheumatoid arthritis [RA]) have meibomian gland dysfunction (MGD). We sought to test our hypothesis.

Methods: Subjects with pSS, sSS + SLE, sSS + RA, and non-SS-related MGD were recruited from the Sjögren's Syndrome Foundation or outpatient clinics at Tufts University School of Dental Medicine or Brigham and Women's Hospital. The control population was recruited from the Greater Boston area. After providing written informed consent, the subjects underwent an eye examination and/or completed two questionnaires that assess symptoms of dry eye disease (DED).

Results: Our results demonstrate that pSS and sSS patients have MGD. These subjects had meibomian gland orifice metaplasia, an increased number of occluded meibomian gland orifices, and a reduced quality of meibomian gland secretions. Further, patients with pSS, sSS + SLE, sSS + RA, and MGD had significant alterations in their tear film, lid margin, cornea, and conjunctiva. Symptoms of DED were increased ∼10-fold in all pSS, sSS, and MGD groups relative to controls.

Conclusions: Our findings support our hypothesis and show that individuals with pSS, sSS + SLE, and sSS + RA have MGD. In addition, our study indicates that patients with pSS and sSS have both aqueous-deficient and evaporative DED.

Citing Articles

Meibomian gland dropout of upper eyelids as a novel biomarker for early diagnosis of primary Sjögren's syndrome: a pilot study.

Wu J, Liang Y, Shi F, Tu X, Zhang J, Qiu Q Ther Adv Musculoskelet Dis. 2024; 16:1759720X241274726.

PMID: 39228398 PMC: 11369872. DOI: 10.1177/1759720X241274726.


Using machine learning model explanations to identify proteins related to severity of meibomian gland dysfunction.

Storas A, Fineide F, Magno M, Thiede B, Chen X, Strumke I Sci Rep. 2023; 13(1):22946.

PMID: 38135766 PMC: 10746717. DOI: 10.1038/s41598-023-50342-7.


Artificial intelligence-assisted diagnosis of ocular surface diseases.

Zhang Z, Wang Y, Zhang H, Samusak A, Rao H, Xiao C Front Cell Dev Biol. 2023; 11:1133680.

PMID: 36875760 PMC: 9981656. DOI: 10.3389/fcell.2023.1133680.


Relationship between clinical parameters and quality of life in primary Sjögren's Syndrome: a prospective study.

Greenan E, Pilson Q, Ni Gabhann-Dromgoole J, Murphy C Eye (Lond). 2023; 37(13):2685-2692.

PMID: 36658430 PMC: 10482965. DOI: 10.1038/s41433-023-02386-2.


Case report: Immune-mediated meibomian gland dysfunction following pembrolizumab therapy for advanced urothelial carcinoma.

Nguyen C, Su C, Morgan M, Alva A Front Oncol. 2022; 12:1000023.

PMID: 36276085 PMC: 9582237. DOI: 10.3389/fonc.2022.1000023.